Enlivex Therapeutics Ltd

Enlivex Ltd., together with its subsidiaries, is a clinical-stage macrophage reprogramming immunotherapy company based in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis. The company is developing an intra-articular injection of AllocetraTM for knee osteoarthritis in a phase 1/2 trial, intra-articular AllocetraTM for osteoarthritis of the temporomandibular joint (TMJ), and Allocetra-OTS for organ failure in adult sepsis patients in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026; it was founded in 2005 and is headquartered in Ness Ziona, Israel.